Cognitive concomitants of dopamine system stimulation in Parkinsonian patients

ERICH MOHR,* GIOVANNI FABBRI,† STEFANO RUGGIERI,‡ PAUL FEDIO,* THOMAS N CHASE†

From the Medical Neurology Branch,* Experimental Therapeutics Branch,† National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD, USA, and the Prima Clinica Neurologica Universita, degli Studi La Sapienza,‡ Rome, Italy

SUMMARY Verbal, visuospatial and motor functions were studied in eight Parkinsonian patients both during levodopa stimulated and unstimulated state and in eight matched, untreated, healthy controls. Profound changes in patients' motor status were accompanied by relatively selective effects on delayed verbal memory, a function which was also most impaired compared with controls. With dopaminomimetic therapy, tests of delayed verbal memory consistently improved, but did not reach control performance levels. These results could indicate a functional impairment in the mesocortical dopamine system, which can be attenuated, but not entirely corrected, by dopaminomimetic therapy.

Considerable evidence suggests that dopamine containing neurons participate in the regulation of certain cognitive processes. In the experimental animal, procedures which attenuate central dopaminergic function have been reported to compromise delayed spatial alternation tasks,¹ acquisition of active avoidance² and maintenance of normal spatial working memory.³ Pharmacological stimulation of the dopamine system, on the other hand, tends to reverse some of these performance deficits.⁴–⁶ In man, dopaminergic hypofunction has been implicated in the pathogenesis of Alzheimer's dementia,⁷ as well as in certain intellectual deficits occurring in Parkinson's disease.⁸ Clinical studies suggest that cognitive deficits in Parkinsonian patients involve mainly memory and learning.⁹ Specifically, while semantic or knowledge memory, notably context-free general principles, associations and rules¹⁰ is reportedly unimpaired, performance in the realm of episodic memory, notably context-bound knowledge, including information learned in the laboratory,¹¹ may be compromised in untreated Parkinsonian individuals.¹¹ Conversely, although reports of cognitive improvement with levodopa treatment in Parkinsonian patients are equivocal,¹²–¹⁴ treatment with dopaminomimetics has been reported to improve effortful memory in normal individuals.¹⁵ Notwithstanding these observations, the precise contribution of the dopamine system to defined aspects of human intellectual function remains uncertain. In an attempt to explore this matter, verbal and visuospatial functions were studied in Parkinsonian patients both during levodopa stimulated and unstimulated states.

Methods

Eight patients (five men, three women; mean ± SEM age 58 ± 4·7 years, range 29–70), with the diagnosis of idiopathic Parkinson's disease and eight normal control subjects (five men, three women, mean ± SEM age 59 ± 3·1 years, range 30–71), consented to participate in this study after full disclosure of its purpose, risks and potential benefits. Symptoms had been present in the patient group for 2 to 21 years (11·1 ± 2·1) and unmedicated severity ranged from 2 to 4 on the Hoehn and Yahr Scale.¹⁶ All patients had received levodopa for 1 to 12 years (mean 7·9 ± 1·6). Each now manifested consistent wearing-off phenomena, characterised by a loss of motor response 2 to 4 hours after levodopa administration. All normal control subjects underwent a routine neurological and neuropsychological evaluation to assure that no significant illness was present.

All study subjects received an extensive assessment of intellectual and memory functions. Psychometric tests of
Cognitive concomitants of dopamine system stimulation in Parkinsonian patients

intelligence during optimal levodopa treatment, revealed low to high average functioning in the patient group, whose educational level ranged from 12 to 20 years (15 ± 10); Wechsler Adult Intelligence Scale-Revised\textsuperscript{17} Full Scale IQ 100 ± 3·0 (range 92–115); Verbal IQ 104 ± 4·1 (range 88–120); Performance IQ 97 ± 3·7 (range 74–107); Wechsler Memory Scale\textsuperscript{18} 111 ± 5·6 (range 95–141); Mattis Dementia Rating Scale\textsuperscript{19} 137 ± 2·2 (range 126–143). The normal control group (mean education 13·5 ± 0·4, range 12–16 years), by comparison showed average to superior intellectual and mnemonic function (Full Scale IQ 115·5 ± 2·8, range 103–141; Verbal IQ 114 ± 2·6, range 98–134; Performance IQ 114·6 ± 3·3, range 95–135; Memory Quotient 121·6 ± 3·6, range 101–143). The Mattis dementia rating scale revealed no evidence of dementia in the controls (141 ± 0·4, range 139–144).

Throughout the study, patients received levodopa-carbidopa (Sinemet) each at their optimal antiparkinsonian dose (125 to 230 mg per dose of levodopa) every 2 to 4 hours while awake. Overall motor function was monitored by the patient and by a neurologist, familiar with the subject’s individual response to antiparkinsonian treatment; both were asked to identify on periods during which Parkinsonian signs abated and dyskinesias sometimes appeared, from off periods, when Parkinsonian signs returned.

Motor and cognitive function were then assessed by a neurologist and a neuropsychologist who had no prior knowledge of these designations. Parkinsonian and dyskinesia severity was evaluated first, each on a scale of 0 (absent) to 4 (very severe); venous blood was then drawn for the determination of plasma levodopa levels; finally neuropsychologic testing was carried out. Data were analysed only from those sessions during which motor function remained stable. The 50 minute assessment sessions during on and off periods occurred in random order, over 4 non-consecutive days.

Neuropsychological tests were selected specifically to sample those domains reportedly impaired in untreated Parkinsonian patients, in order to optimise chances of detecting treatment related changes in cognition. These included in particular memory, learning and visuospatial orientation.\textsuperscript{11,24,26} Alternative forms of the following neurobehavioural instruments were administered in such a manner that speed or accuracy of motor performance did not affect scoring:

- **Verbal Fluency** Patients were given 60 seconds to name as many supermarket items as possible.\textsuperscript{19}
- **Embedded Figures Test** Patients were asked to recognise a simple geometric design in one of four complex patterns.\textsuperscript{20}
- **Logical Memory** The narrative account of a complex event had to be recalled verbatim.\textsuperscript{18}
- **Paired Associate Words** A four trial series (three immediate, one 30 minute delayed recall) of six easy paired associates (for example, gold-silver) and four hard paired associates (such as school-grocery) were read to patients in 1 second intervals. After each series, patients were furnished with the first word of the pair and asked to recall the correct associate.\textsuperscript{18}
- **Visual Form Discrimination Test** A set of figures was presented for 10 seconds and patients were asked to select the correct set among four alternative designs.\textsuperscript{21} In the delayed recall portion of this test, a 15 second interval separated the initial presentation and the multiple choice condition.

All data are presented as the mean ± SEM and were statistically evaluated by standard repeated measures Analysis of Variance procedures\textsuperscript{22} and when appropriate, with correlation measures.\textsuperscript{23}

### Results

Motor function evidenced a consistent (p < 0·001) response to levodopa therapy (table). During on periods, as identified by patient and physician global assessments, plasma drug levels averaged nearly 3·5 fold higher (5·5 ± 1·2 µg/ml) than during off periods (1·6 ± 0·71 µg/ml; p < 0·001). Patients’ and physician’s assessment of on and off state were in perfect agreement. While in the on state, neurologists’ ratings indicated that Parkinsonian signs were absent to mild with scores ranging from 0 to 1, while dyskinesias were absent to moderately severe, with scores between

### Table Effect of levodopa on motor and cognitive function

<table>
<thead>
<tr>
<th></th>
<th>Parkinsonian patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Maximum score</td>
<td>Off</td>
</tr>
<tr>
<td><strong>Motor effects:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinsonian score</td>
<td>4</td>
<td>18 ± 0·15</td>
</tr>
<tr>
<td>Dykinesia score</td>
<td>4</td>
<td>0 ± 0</td>
</tr>
<tr>
<td><strong>Learning-dissociated effects:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verbal fluency</td>
<td></td>
<td>16 ± 1·1</td>
</tr>
<tr>
<td>Embedded figures</td>
<td>5</td>
<td>3·7 ± 0·41</td>
</tr>
<tr>
<td><strong>Immediate memory effects:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Logical memory</td>
<td>23</td>
<td>4·4 ± 0·68</td>
</tr>
<tr>
<td>Paired associates</td>
<td>7</td>
<td>3·4 ± 0·22</td>
</tr>
<tr>
<td>Visual retention</td>
<td>4</td>
<td>2·6 ± 0·37</td>
</tr>
<tr>
<td><strong>Delayed memory effects:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Logical memory</td>
<td>23</td>
<td>2·9 ± 0·53</td>
</tr>
<tr>
<td>Paired associates</td>
<td>7</td>
<td>3·8 ± 0·37</td>
</tr>
<tr>
<td>Visual retention</td>
<td>4</td>
<td>2·7 ± 0·24</td>
</tr>
</tbody>
</table>

* p < 0·001; † p < 0·05 for difference from off period by ANOVA for repeated measures.
† p < 0·01 for difference between controls and Parkinsonian patients both during “on” and “off” state.
between 0 and 3 (table). In contrast, during off periods, Parkinsonian scores ranged from mild to moderately severe (1 to 3), while no patient manifested dyskinesia.

Cognitive function exhibited a more complex pattern of response to levodopa stimulation (table). Neuropsychological tests which are largely dissociated from the context of learning (Verbal Fluency and Embedded Figures), yielded no differences between on and off periods. Similarly, tasks involving immediate memory, both in the verbal and the visuospatial realm, also failed to discriminate between the two states.

Delayed memory tests did however suggest differences between the on and off periods (table). Average performance on the Logical Memory and the Paired Associates tasks showed a small, albeit consistent, improvement during the levodopa stimulated state ($p < 0.05$). For the individual patient, six of eight had a performance increment on the Logical Memory task, while five of eight improved on the Paired Associates test (fig 1). Analysis of the Paired Associates results revealed essentially identical responses between the on and off states on the first trial and the appearance of differences only on subsequent trials (fig 2). There was no significant correlation between the motor response to levodopa and the cognitive response as measured by either of these tests. Significant alterations in delayed memory could be documented only on the verbal tasks. The Visual Retention test for visuospatial memory failed to demonstrate any consistent differences (table): four patients improved, one remained unchanged and three deteriorated.

A comparison of cognitive performance patterns in Parkinsonian patients with those in normal controls, revealed significant decrements in the patient group of all those functions showing significant differences between the on and off states ($p < 0.01$). This held true both for comparison of normals with patients when they were “on” as well as when they were “off” (table). Conversely, with the exception of visual disembedding (Embedded Figures), none of the tasks showing “no differences” between patients' on and off period, evidenced significant performance decrements compared to control scores.

Discussion

The present results support the view that pharmacological activation of the dopamine system can affect intellectual function in patients with Parkinson’s disease. Individuals with predictable wearing-off phenomena were chosen for study so that periods of levodopa-induced stimulation of central dopaminergic mechanisms could be reliably distinguished from periods in which motor function returned to its untreated state. The on-off states were studied in random order on non-consecutive days, in order to limit the possibility of result contamination due to extraneous factors. The assertion that neuropsychological tests used in this study were essentially unaffected by the patients’ motor function, gained some empirical support from the absence of any cor-

![Fig 1 Delayed memory effects: Logical Memory and Paired Associates—individual scores.](http://jnnp.bmj.com/)

![Fig 2 Paired Associate learning by trial.](http://jnnp.bmj.com/)
Cognitive concomitants of dopamine system stimulation in Parkinsonian patients

Recent investigations in the experimental animal further support the concept that the dopamine system might be involved in memory functioning. The dopamine antagonist, haloperidol, reportedly disrupts both working and reference memory for a search task in rats with mesocortical damage.29 Lesioning of rat mesocortical and mesolimbic dopaminergic projections from the A-10 nucleus impaired retention of delayed alternation,3 while catecholamine depletion in the pre-frontal cortex of Rhesus monkeys reduced learning on a similar task, a deficit reversible with administration of levodopa.4 Moreover, biochemical results suggest that cortical dopamine containing neurons facilitate learning of a delayed alternation task in non-drug treated animals.30

Observations deriving from this study could have important implications for the treatment of specific cognitive deficits in both Parkinsonian and non-parkinsonian individuals. Clearly, the impact of antiparkinsonian therapy on extrapyramidal motor function is much more impressive than on cognitive performance, a finding which is in agreement with earlier assertions.24 26 The profound changes in motor performance probably reflect hypofunction of the nigrostriatal dopaminergic system, while the relatively mild cognitive differences between on and off state might indicate a compromise in the functional integrity of another part of the dopaminergic system, particularly the mesocortical pathway. Indeed, the mesocortical system has been implicated in the pathophysiology of Parkinsonism both by direct biochemical evidence31 32 as well as by the indirect neurobehavioural evidence presented here and elsewhere.24 27 Taken together, the mesocortical system may well account for certain aspects of the cognitive decline in some Parkinsonian patients, particularly in the delayed recall of newly learned materials. It remains to be determined whether Parkinsonian patients more cognitively impaired than present subjects would derive greater benefit from dopaminomimetic treatment on these delayed memory tasks. Finally, if such therapeutic intervention can ameliorate certain aspects of memory failure in Parkinson’s disease, the possibility of mesocortical dopamine system dysfunction in other disorders may merit further investigative attention.

References


3 Beatty WW, Rush JR. Spatial working memory in rats: effects of...


